- Home
- ILPT vs PRQR Comparison
ILPT vs PRQR Comparison
Compare ILPT & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILPT
- PRQR
- Stock Information
- Founded
- ILPT 2017
- PRQR 2012
- Country
- ILPT United States
- PRQR Netherlands
- Employees
- ILPT N/A
- PRQR N/A
- Industry
- ILPT Real Estate Investment Trusts
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- ILPT Real Estate
- PRQR Health Care
- Exchange
- ILPT Nasdaq
- PRQR Nasdaq
- Market Cap
- ILPT 217.6M
- PRQR 179.1M
- IPO Year
- ILPT 2018
- PRQR 2014
- Fundamental
- Price
- ILPT $5.48
- PRQR $2.35
- Analyst Decision
- ILPT Buy
- PRQR Strong Buy
- Analyst Count
- ILPT 2
- PRQR 8
- Target Price
- ILPT $10.00
- PRQR $8.88
- AVG Volume (30 Days)
- ILPT 704.6K
- PRQR 365.1K
- Earning Date
- ILPT 07-29-2025
- PRQR 08-07-2025
- Dividend Yield
- ILPT 0.74%
- PRQR N/A
- EPS Growth
- ILPT N/A
- PRQR N/A
- EPS
- ILPT N/A
- PRQR N/A
- Revenue
- ILPT $441,992,000.00
- PRQR $21,212,711.00
- Revenue This Year
- ILPT $3.09
- PRQR N/A
- Revenue Next Year
- ILPT $1.79
- PRQR N/A
- P/E Ratio
- ILPT N/A
- PRQR N/A
- Revenue Growth
- ILPT 0.61
- PRQR 85.91
- 52 Week Low
- ILPT $2.45
- PRQR $1.07
- 52 Week High
- ILPT $5.58
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- ILPT 79.27
- PRQR 66.90
- Support Level
- ILPT $4.50
- PRQR $2.10
- Resistance Level
- ILPT $4.77
- PRQR $2.18
- Average True Range (ATR)
- ILPT 0.20
- PRQR 0.13
- MACD
- ILPT 0.02
- PRQR 0.01
- Stochastic Oscillator
- ILPT 98.46
- PRQR 56.92
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.